Sale!

Genome Based Therapeutics Targeted Drug Discovery and Development 1st Edition by Institute of Medicine,Board on Health Sciences Policy,Roundtable on Translating Genomic Based Research for Health,Steve Olson,Adam C Berger ISBN 0309260248 978-0309260244

Original price was: $50.00.Current price is: $35.00.

Genome Based Therapeutics Targeted Drug Discovery and Development Workshop Summary 1st Edition Institute Of Medicine Digital Instant Download

Author(s): Institute Of Medicine, Board On Health Sciences Policy, Roundtable on Translating Genomic-Based
ISBN(s): 9780309260244, 0309260248
Edition: 1
File Details: PDF, 5.33 MB
Year: 2012
Language: english
SKU: EB-10820992 Category: Tags: , ,

Genome Based Therapeutics Targeted Drug Discovery and Development 1st Edition by Institute of Medicine, Board on Health Sciences Policy, Roundtable on Translating Genomic-Based Research for Health, Steve Olson, Adam C. Berger  – Ebook PDF Instant Download/Delivery: 0309260248, 978-0309260244

Full download Genome Based Therapeutics Targeted Drug Discovery and Development 1st Edition after payment

 

 

Product details:

ISBN 10: 0309260248 

ISBN 13: 978-0309260244

Author: Institute of Medicine, Board on Health Sciences Policy, Roundtable on Translating Genomic-Based Research for Health, Steve Olson, Adam C. Berger 

“The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in regulatory barriers, the rising costs of scientific inquiry, a decrease in research and development efficiency, the downstream effects of patient expirations on investment, and the lack of production models that have successfully incorporated new technology. Regardless, this trajectory is not economically sustainable for the businesses involved, and, in response, many companies are turning toward collaborative models of drug development, whether with other industrial firms, academia, or government. Introducing greater efficiency and knowledge into these new models and aligning incentives among participants may help to reverse the trends highlighted above, while producing more effective drugs in the process. Genome-based therapeutics explains that new technologies have the potential to open up avenues of development and to identify new drug targets to pursue. Specifically, improved validation of gene-disease associations through genomics research has the potential to revolutionize drug production and lower development costs. Genetic information has helped developers by increasing their understanding of the mechanisms of disease as well as individual patients’ reactions to their medications. There is a need to identify the success factors for the various models that are being developed, whether they are industry-led, academia-led, or collaborations between the two. Genome-Based Therapeutics summarizes a workshop that was held on March 21, 2012, titled New paradigms in drug discovery: how genomic data are being used to revolutionize the drug discovery and development process. At this workshop the goal was to examine the general approaches being used to apply successes achieved so far, and the challenges ahead”–Publisher’s description.

Table of contents:

The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in regulatory barriers, the rising costs of scientific inquiry, a decrease in research and development efficiency, the downstream effects of patient expirations on investment, and the lack of production models that have successfully incorporated new technology. Regardless, this trajectory is not economically sustainable for the businesses involved, and, in response, many companies are turning toward collaborative models of drug development, whether with other industrial firms, academia, or government. Introducing greater efficiency and knowledge into these new models and aligning incentives among participants may help to reverse the trends highlighted above, while producing more effective drugs in the process.

Genome-Based Therapeutics explains that new technologies have the potential to open up avenues of development and to identify new drug targets to pursue. Specifically, improved validation of gene-disease associations through genomics research has the potential to revolutionize drug production and lower development costs. Genetic information has helped developers by increasing their understanding of the mechanisms of disease as well as individual patients’ reactions to their medications. There is a need to identify the success factors for the various models that are being developed, whether they are industry-led, academia-led, or collaborations between the two.

Genome-Based Therapeutics summarizes a workshop that was held on March 21, 2012, titled New Paradigms in Drug Discovery: How Genomic Data Are Being Used to Revolutionize the Drug Discovery and Development Process. At this workshop the goal was to examine the general approaches being used to apply successes achieved so far, and the challenges ahead.

People also search for:

genome based therapeutics targeted
    
gene based therapies
    
gene targeted therapy
    
genome targeting
    
gene based medicine

Tags: Institute of Medicine, Board on Health Sciences Policy, Roundtable on Translating Genomic Based Research for Health, Steve Olson, Adam C Berger, Genome Based Therapeutics, Targeted Drug Discovery, Drug Development